Dr. David Koren Provides Perspective for Medscape Article on Switching Patients with HIV to Injectable Long-Acting Cabotegravir/Rilpivirine

David Koren, PharmD, MPH, BCPS, AAHIVP, Adjunct Clinical Assistant Professor in the Department of Pharmacy Practice at the Temple University School of Pharmacy, Adjunct Assistant Professor in the Department of Medicine at the Lewis Katz School of Medicine at Temple University and Clinical Pharmacist Specialist in Infectious Diseases/HIV at Temple University Hospital, provided perspective to Medscape about switching patients with HIV to injectable long-acting cabotegravir/rilpivirine (CAB/RPV LA). CAB/RPV LA was approved by the U.S. Food and Drug Administration (FDA) in January 2021 and is considered an optimization strategy for individuals with HIV whose virus is suppressed by oral antiretroviral therapy and might prefer monthly injections versus daily oral therapy. The New York State Department of Health AIDS Institute recently released new clinical guidelines for its use.